Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease.

Gyoneva S, Shapiro L, Lazo C, Garnier-Amblard E, Smith Y, Miller GW, Traynelis SF.

Neurobiol Dis. 2014 Jul;67:191-202. doi: 10.1016/j.nbd.2014.03.004. Epub 2014 Mar 13.

2.

Altered motility of plaque-associated microglia in a model of Alzheimer's disease.

Gyoneva S, Swanger SA, Zhang J, Weinshenker D, Traynelis SF.

Neuroscience. 2016 Aug 25;330:410-20. doi: 10.1016/j.neuroscience.2016.05.061. Epub 2016 Jun 7.

3.

Systemic inflammation regulates microglial responses to tissue damage in vivo.

Gyoneva S, Davalos D, Biswas D, Swanger SA, Garnier-Amblard E, Loth F, Akassoglou K, Traynelis SF.

Glia. 2014 Aug;62(8):1345-60. doi: 10.1002/glia.22686. Epub 2014 May 7.

4.

Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Yasuda Y, Shinagawa R, Yamada M, Mori T, Tateishi N, Fujita S.

Brain Res. 2007 Mar 23;1138:196-202. Epub 2006 Dec 23.

PMID:
17275793
5.

Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes.

Parillaud VR, Lornet G, Monnet Y, Privat AL, Haddad AT, Brochard V, Bekaert A, de Chanville CB, Hirsch EC, Combadière C, Hunot S, Lobsiger CS.

J Neuroinflammation. 2017 Mar 21;14(1):60. doi: 10.1186/s12974-017-0830-9.

6.

Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.

Vázquez-Claverie M, Garrido-Gil P, San Sebastián W, Izal-Azcárate A, Belzunegui S, Marcilla I, López B, Luquin MR.

J Neuropathol Exp Neurol. 2009 Sep;68(9):977-84. doi: 10.1097/NEN.0b013e3181b35e41.

PMID:
19680145
7.
8.

Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.

Xu K, Di Luca DG, Orrú M, Xu Y, Chen JF, Schwarzschild MA.

Neuroscience. 2016 May 13;322:129-37. doi: 10.1016/j.neuroscience.2016.02.035. Epub 2016 Feb 22.

9.

Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease.

Ren B, Zhang YX, Zhou HX, Sun FW, Zhang ZF, Wei Z, Zhang CY, Si DW.

J Neurol Sci. 2015 Jan 15;348(1-2):142-52. doi: 10.1016/j.jns.2014.11.026. Epub 2014 Nov 28.

PMID:
25491263
10.

α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease.

Kim BW, Koppula S, Kumar H, Park JY, Kim IW, More SV, Kim IS, Han SD, Kim SK, Yoon SH, Choi DK.

Neuropharmacology. 2015 Oct;97:46-57. doi: 10.1016/j.neuropharm.2015.04.037. Epub 2015 May 15.

PMID:
25983275
11.

Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation.

Chung YC, Bok E, Huh SH, Park JY, Yoon SH, Kim SR, Kim YS, Maeng S, Park SH, Jin BK.

J Immunol. 2011 Dec 15;187(12):6508-17. doi: 10.4049/jimmunol.1102435. Epub 2011 Nov 11.

12.
13.

Injury-stimulated Sonic hedgehog expression in microglia contributes to neuroinflammatory response in the MPTP model of Parkinson's disease.

Lee JH, Chung YC, Bok E, Lee H, Huh SH, Lee JE, Jin BK, Ko HW.

Biochem Biophys Res Commun. 2017 Jan 22;482(4):980-986. doi: 10.1016/j.bbrc.2016.11.144. Epub 2016 Nov 27.

PMID:
27899315
14.

Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism.

Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C, Kinugawa K, Prigent A, Höglinger G, Hamon M, Tronche F, Hirsch EC, Vyas S.

Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6632-7. doi: 10.1073/pnas.1017820108. Epub 2011 Apr 5.

15.

Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications.

Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, Lucius R.

Curr Pharm Des. 2007;13(18):1925-8. Review.

PMID:
17584117
16.

Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease.

Panicker N, Saminathan H, Jin H, Neal M, Harischandra DS, Gordon R, Kanthasamy K, Lawana V, Sarkar S, Luo J, Anantharam V, Kanthasamy AG, Kanthasamy A.

J Neurosci. 2015 Jul 8;35(27):10058-77. doi: 10.1523/JNEUROSCI.0302-15.2015.

17.

Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.

Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M.

J Neurochem. 2009 Dec;111(6):1478-89. doi: 10.1111/j.1471-4159.2009.06425.x. Epub 2009 Oct 8.

18.

Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease.

Kurkowska-Jastrzebska I, Bałkowiec-Iskra E, Ciesielska A, Joniec I, Cudna A, Zaremba MM, Członkowski A, Członkowska A.

Int Immunopharmacol. 2009 Jun;9(6):781-91. doi: 10.1016/j.intimp.2009.03.003. Epub 2009 Mar 13.

PMID:
19286483
19.
20.

Differential regulation of microglial motility by ATP/ADP and adenosine.

Gyoneva S, Orr AG, Traynelis SF.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S195-9. doi: 10.1016/S1353-8020(09)70813-2. Review.

PMID:
20082989

Supplemental Content

Support Center